In Stock: Mounjaro (Tirzepatide) SC Injection
Mounjaro (Tirzepatide) 2.5mg/0.5ml SC Injection Mounjaro (Tirzepatide) 5mg/0.5ml SC Injection Mounjaro (Tirzepatide) 7.5mg/0.5ml SC Injection Mounjaro (Tirzepatide) 10mg/0.5ml SC Injection
Semaglutide (Wegovy) for Weight Management
Dose Escalation Schedule Weeks 1-4 - 0.25 mg SC weekly Weeks 5-8 - 0.5 mg SC weekly Weeks 9-12 - 1 mg SC weekly Week 13-16 - 1.7 mg SC…
Leqvio (Inclisiran) Dosing & Administration (Instructions for Use)
Dosing Regimen, Administration and Instructions for Use
Semaglutide (Ozempic) Instructions for Use
Indications: 1) Diabetes 2) Weight Loss
Mounjaro (Tirzepatide) Instructions for Use
Mounjaro (Tirzepatide) Indications: Diabetes & Weight Loss Instructions for Use
Vtama (tapinarof) 1% Topical Cream (60 gram)
Vtama (tapinarof) 1% Topical Cream for the Treatment of Plaque Psoriasis is Available
Saxenda (Liraglutide), Wegovy (Semaglutide) and Mounjaro (Tirzepatide) SC Injections for Type 2 Diabetes and Weight Management
Drug Info: ApoThera Drug Disease Clinical Support App Diabetes Mellitus, Type 2 Initial Dose – 2.5 mg SC every week x 4 weeks Maintenance Dose – Increase to 5 mg…
FDA Approves Lilly and Incyte’s OLUMIANT (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib), a once-daily pill, as a first-in-disease systemic treatment…
Risankizumab (SKYRIZI) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn’s Disease in Adults
Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely active Crohn's disease,…